Cytosorbents CEO buys 200K shares at $0.35

Rhea-AI Filing Summary

Cytosorbents Corp (CTSO) reports that Chief Executive Officer and director Phillip P. Chan purchased 200,000 shares of Common Stock on September 4, 2026, in an open-market transaction at a weighted average price of $0.35 per share, with individual trades ranging from $0.3470 to $0.3599.

Following this purchase, Chan holds a reported total of 1,944,432 shares, consisting of Common Stock and restricted stock units that vest upon specified conditions, and the report notes that these amounts were not adjusted for a reverse stock split that occurred on September 8, 2026; no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 1 txn

Insider Chan Phillip P.

Role Chief Executive Officer

Bought 200,000 shs ($70K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2, F3, F4	200,000	$0.35	$70K

Holdings After Transaction: Common Stock — 1,944,432 shares (Direct)

Footnotes (4)

1. F1. The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3470 to $0.3599, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
2. F2. Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
3. F3. (continued from footnote 2) (ii) 52,800 RSUs of 105,600 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 1,475,632 shares of Common Stock owned by the Reporting Person.
4. F4. The shares reported herein were not adjusted to reflect the Issuer's reverse stock split that occurred on September 8, 2026.

Key Figures

Shares purchased: 200,000 shares Weighted average purchase price: $0.35 per share Purchase price range: $0.3470–$0.3599 per share +5 more

8 metrics

Shares purchased 200,000 shares Open-market purchase by CEO on September 4, 2026

Weighted average purchase price $0.35 per share Price paid for the 200,000-share purchase

Purchase price range $0.3470–$0.3599 per share Range of prices for multiple trades making up the purchase

Shares owned after transaction 1,944,432 shares CEO’s reported total holdings, including RSUs and Common Stock, prior to reverse split adjustment

RSUs contingent on Change In Control 216,000 RSUs RSUs from 2015–2018 grants that settle upon a defined Change In Control

Time-vesting RSUs from August 8, 2025 grant 52,800 RSUs Half of 105,600 RSUs vesting over two years, subject to continued service

Common Stock directly owned 1,475,632 shares Common Stock owned by the CEO included in post-transaction total

Reverse stock split date September 8, 2026 Date of Issuer’s reverse stock split, not yet reflected in reported share counts

Key Terms

restricted stock units, Change In Control, Long-Term Incentive Plan, reverse stock split

4 terms

restricted stock units financial

"Includes: (i) the following restricted stock units ("RSUs") that will be settled"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Change In Control financial

"RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control""

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Long-Term Incentive Plan financial

"as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan"

A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.

reverse stock split financial

"The shares reported herein were not adjusted to reflect the Issuer's reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

What insider transaction did CTSO report for CEO Phillip P. Chan?

Cytosorbents reported that CEO Phillip P. Chan purchased 200,000 shares of Common Stock on September 4, 2026, in an open-market transaction at a weighted average price of $0.35 per share, with trade prices ranging from $0.3470 to $0.3599.

How many CTSO shares does the CEO hold after this transaction?

After the reported transaction, Phillip P. Chan holds a total of 1,944,432 shares, which includes Common Stock and restricted stock units that will settle into Common Stock upon vesting or a specified "Change In Control" event, and the amounts have not been adjusted for a later reverse stock split.

Was the CTSO CEO’s 200,000-share purchase under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is affirmed for this transaction, and the related footnote describes it as an open market purchase made by the reporting person.

What price range did the CTSO CEO pay for the purchased shares?

The reported weighted average purchase price was $0.35 per share. The filing explains that the individual trades for the 200,000-share purchase occurred at prices ranging from $0.3470 to $0.3599, inclusive.

How are restricted stock units included in the CTSO CEO’s reported holdings?

The reported total of 1,944,432 shares includes several grants of restricted stock units (RSUs) that will be settled into Common Stock upon vesting, including RSUs that vest upon a defined "Change In Control" and RSUs that vest over time, plus Common Stock directly owned.

What does the filing say about CTSO’s reverse stock split in relation to these holdings?

A footnote states that the shares reported were not adjusted to reflect a reverse stock split of Cytosorbents that occurred on September 8, 2026, meaning the reported share counts predate that adjustment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:06 PM Accepted by SEC EDGAR 09/09/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Phillip P.

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		P		200,000(1)	A	$0.35	1,944,432(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3470 to $0.3599, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

3. (continued from footnote 2) (ii) 52,800 RSUs of 105,600 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 1,475,632 shares of Common Stock owned by the Reporting Person.

4. The shares reported herein were not adjusted to reflect the Issuer's reverse stock split that occurred on September 8, 2026.

	/s/ Phillip P. Chan	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)